12:00 AM
 | 
Jul 19, 2016
 |  BC Extra  |  Company News

Ziopharm says patient death was unrelated to treatment

Ziopharm Oncology Inc. (NASDAQ:ZIOP) said a patient death disclosed on Friday was not related to treatment with gene therapy candidate Ad-RTS-hIL-12. The death, due to intracranial hemorrhage, was one of three Ziopharm had said occurred in a Phase...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >